GlassScriptPhysician profile
John C Welker
NPI 1346477221
$9,350.39
in general payments reported to CMS, 2019-2025
10 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.10 · 2020: $16.82 · 2021: $553 · 2022: $1,122 · 2023: $4,321 · 2024: $1,938 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,984 · Consulting Fee: $2,550 · Travel and Lodging: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,983.93 |
| Consulting Fee | $2,550.00 |
| Travel and Lodging | $1,043.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,672.98 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Therapies |
| Abbott Laboratories | $414.55 | 2023-2024 | Proclaim, Eterna, Octrode |
| Painteq LLC | $67.18 | 2023-2024 | Painteq |
| Abbvie INC. | $43.90 | 2021 | |
| Stratus Medical, LLC | $40.89 | 2023 | Nimbus |
| Globus Medical, INC. | $36.39 | 2025 | Senza |
| Pfizer INC. | $23.77 | 2025 | |
| Collegium Pharmaceutical, INC. | $20.57 | 2025 | Xtampza |
| Nevro Corp. | $20.25 | 2023 | Senza |
| Spr Therapeutics, INC | $9.91 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Welker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.